26677
document
The safety and efficacy of terazosin in the treatment of essential hypertension in blacks . Terazosin , a new selective alpha 1-adrenergic receptor antagonist , has been found to be an effective antihypertensive agent . In a series of studies , the safety and efficacy of terazosin , alone and in combination with other antihypertensive agents , were evaluated in 1180 black patients with mild to moderate essential hypertension . Terazosin was effective in lowering blood pressure when administered alone ( in dosages of 1 to 80 mg/day ) and when prescribed ( in dosages of 1 to 20 mg/day ) in combination with other antihypertensive agents . In elderly black patients , terazosin , 1 to 10 mg daily , was as effective in lowering blood pressure as propranolol ( 40 to 120 mg twice daily ) . Changes ( mean +/- SE ) in sitting diastolic blood pressure from baseline were -8.1 +/- 1.4 mm Hg for terazosin and -5.0 +/- 1.5 mm Hg for propranolol . Terazosin ( 5 mg ) combined with methyclothiazide ( 2.5 to 5 mg ) produced a significantly greater ( p less than 0.01 ) antihypertensive effect than that of terazosin alone . Changes ( mean +/- SE ) in standing diastolic blood pressure from baseline were -7.9 +/- 2.0 mm Hg for terazosin alone , -15.1 +/- 2.1 mm Hg for terazosin plus 2.5 mg of methyclothiazide , and -15.0 +/- 2.0 mm Hg for terazosin plus 5 mg of methyclothiazide . Terazosin had a favorable effect on serum lipid levels and appeared to compensate for the negative lipid effects associated with diuretics and beta-blockers when used in combination with these agents . Terazosin , alone and combined with other antihypertensive agents , was well tolerated with minimal side effects in black hypertensive patients .
26678
Intervention_Pharmacological
terazosin
26679
Intervention_Pharmacological
Terazosin
26680
Intervention_Pharmacological
terazosin
26681
Intervention_Pharmacological
antihypertensive agents
26682
Intervention_Pharmacological
Terazosin
26683
Intervention_Pharmacological
antihypertensive agents
26684
Intervention_Pharmacological
propranolol
26685
Intervention_Pharmacological
propranolol
26686
Intervention_Pharmacological
Terazosin
26687
Intervention_Pharmacological
terazosin
26688
Intervention_Pharmacological
terazosin
26689
Intervention_Pharmacological
terazosin
26690
Intervention_Pharmacological
2.5 mg of methyclothiazide
26691
Intervention_Pharmacological
terazosin
26692
Intervention_Pharmacological
methyclothiazide
26693
Outcome_Physical
blood pressure
26694
Outcome_Physical
sitting diastolic blood pressure from baseline
26695
Outcome_Physical
antihypertensive effect
26696
Outcome_Physical
standing diastolic blood pressure from baseline
26697
Outcome_Physical
serum lipid levels
26698
Outcome_Physical
tolerated
26699
Participant_Condition
essential hypertension in blacks .
26700
Participant_Sample-size
1180
26701
Participant_Condition
mild to moderate essential hypertension
26702
Participant_Age
elderly
26703
Participant_Condition
hypertensive